ANIK:NSD-Anika Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 37.07

Change

-0.35 (-0.94)%

Market Cap

USD 0.53B

Volume

0.08M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.60 (-1.56%)

USD59.89B 22.57 17.39
MRNA Moderna, Inc

+1.99 (+1.41%)

USD55.80B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-8.94 (-1.74%)

USD54.85B 18.84 14.53
SGEN Seagen Inc

-0.37 (-0.21%)

USD31.76B 67.00 62.62
BNTX BioNTech SE

+7.08 (+6.21%)

USD29.92B -99,999.99 N/A
RPRX Royalty Pharma plc

-1.00 (-2.34%)

USD26.75B 22.60 9.74
ALXN Alexion Pharmaceuticals, Inc

+0.60 (+0.49%)

USD26.73B 28.35 26.92
GMAB Genmab A/S

+0.08 (+0.21%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-19.49 (-7.91%)

USD24.48B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ANIK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -28.51% 27% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.51% 27% F 16% F
Trailing 12 Months  
Capital Gain -35.03% 20% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.03% 20% F 10% F
Trailing 5 Years  
Capital Gain -14.39% 59% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.39% 59% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 3.04% N/A N/A 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.04% N/A N/A 42% F
Risk Return Profile  
Volatility (Standard Deviation) 29.28% N/A N/A 50% F
Risk Adjusted Return 10.37% N/A N/A 39% F
Market Capitalization 0.53B 64% D 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.00 21% F 25% F
Price/Book Ratio 1.91 81% B- 58% F
Price / Cash Flow Ratio 14.37 6% F 25% F
EV/EBITDA 59.11 9% F 14% F
Management Effectiveness  
Return on Equity -1.51% 93% A 51% F
Return on Invested Capital 9.17% 91% A- 77% C+
Return on Assets 1.76% 95% A 66% D
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 18.42 8% F 3% F
Short Percent 14.83% 18% F 14% F
Beta 1.04 72% C- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector